about
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases4-[3,5-Bis(2-hy-droxy-phen-yl)-1H-1,2,4-triazol-1-yl]benzoic acid dimethyl-formamide monosolvate.Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.Aceruloplasminemia: a rare disease - diagnosis and treatment of two cases.Synthetic and natural iron chelators: therapeutic potential and clinical useThe role of iron in the pathogenesis of endometriosis.The Effects of Nutrition, Exercise, and a Praying Program on Reducing Iron Overload in Patients With Beta-Thalassemia Major: A Randomized Clinical Trial.Molecular basis of iron-loading disorders.Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.Deferasirox-TAT(47-57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine.Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox.Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.Chelation of Thallium (III) in Rats Using Combined Deferasirox and Deferiprone Therapy.There is no 'Conundrum' of InsP6.Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.Treatment of mercury vapor toxicity by combining deferasirox and deferiprone in rats.Chelation of thallium by combining deferasirox and desferrioxamine in rats.Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model.Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.Orphan Drugs and Potential Novel Approaches for Therapies of β-Thalassemia: Current Status and Future ExpectationsDeferasirox-coated iron oxide nanoparticles as a potential cytotoxic agent
P2860
Q28388335-8F7CAADA-A06B-470F-8B81-1F6048ACF0D2Q35816061-B1EA865A-3540-4F86-85D3-040578839861Q35911202-F517C8FD-1591-4533-A843-7291EE0B6358Q36153657-3802F380-3477-4185-8DB2-3EAF9C182FBDQ37290073-27E2E677-085E-4930-8E89-FF7EECE6A6EEQ37376157-172150D6-2068-4077-99F8-9DA3BCB66C5BQ37631132-CE23A442-D782-4BEB-9770-E0C92765F76FQ37807528-99AFB443-643B-44E5-B8EA-50E1352BE1ABQ38219588-9A87AE36-0194-4CB4-AEB5-A276141CCC6AQ38854241-AF8CBC83-98FC-4BD9-94CD-FE8C351B8917Q38962101-E5474D4A-FCFB-42D6-8E96-1557C0C216F4Q40521611-8DAD8479-0A12-4E32-98FF-7E00EC47E35FQ42642885-21CA1446-3EE3-472E-BBC8-D7001806DB50Q43090438-C4EB6811-AF10-4D74-99BF-6E29990DC290Q43235333-77EA9F08-1CEC-4666-BA21-C6259B862976Q43413539-1416B675-03E4-4659-9F9A-D2C1A75CC62EQ43942281-EC348E6A-C016-4537-990E-35B3700BB91DQ50482668-5C9AF2C6-6996-4DAE-A5F5-C173D119BD2EQ51040955-26EE1FD5-B546-4BD6-9AD8-7A12602B24AAQ54585888-420EC19F-184A-4AA4-B8A7-E0BA0E453B8CQ57369025-DA0E753F-21AB-4B6A-9068-C92EEFC7AC57
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Deferasirox
@ast
Deferasirox
@en
type
label
Deferasirox
@ast
Deferasirox
@en
prefLabel
Deferasirox
@ast
Deferasirox
@en
P3181
P1433
P1476
Deferasirox
@en
P2093
Susan J Keam
P304
P3181
P356
10.2165/00003495-200767150-00007
P577
2007-01-01T00:00:00Z
P6179
1001188916